All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

Show full item record



Permalink

http://hdl.handle.net/10138/161398

Citation

Strandberg , A Y , Hoti , F J , Strandberg , T E , Christopher , S , Haukka , J & Korhonen , P 2016 , ' All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine ' PLoS One , vol. 11 , no. 3 , 0151910 . DOI: 10.1371/journal.pone.0151910

Title: All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
Author: Strandberg, Arto Y.; Hoti, Fabian J.; Strandberg, Timo E.; Christopher, Solomon; Haukka, Jari; Korhonen, Pasi
Contributor: University of Helsinki, Department of Medicine
Date: 2016-03-31
Language: eng
Number of pages: 13
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/161398
Abstract: Background Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the impact of different types of basal insulins on these endpoints is unclear. Compared to the traditional NPH insulin, the newer, longer-acting insulin analogues detemir and glargine have shown benefits in randomized controlled trials. Whether these advantages translate into lower mortality among users in real life is unknown. Objective To estimate the differences in all-cause and cause-specific mortality rates between new users of basal insulins in a population-based study in Finland. Methods 23 751 individuals aged >= 40 with type 2 diabetes, who initiated basal insulin therapy in 2006-2009 were identified from national registers, with comprehensive data for mortality, causes of death, and background variables. Propensity score matching was performed on characteristics. Follow-up time was up to 4 years (median 1.7 years). Results 2078 deaths incurred. With NPH as reference, the adjusted HRs for all-cause mortality were 0.39 (95% CI, 0.30-0.50) for detemir, and 0.55 (95% CI, 0.44-0.69) for glargine. As compared to glargine, the HR was 0.71 (95% CI, 0.54-0.93) among detemir users. Compared to NPH, the mortality risk for both cardiovascular causes as well as cancer were also significantly lower for glargine, and especially for detemir in adjusted analysis. Furthermore, the results were robust in various sensitivity analyses. Conclusion In real clinical practice, mortality was substantially higher among users of NPH insulin as compared to insulins detemir or glargine. Considering the large number of patients who require insulin therapy, this difference in risk may have major clinical and public health implications. Due to limitations of the observational study design, further investigation using an interventional study design is warranted.
Subject: ACTING INSULIN
CARDIOVASCULAR EVENTS
PROPENSITY SCORE
GLYCEMIC CONTROL
CANCER-RISK
HYPOGLYCEMIA
COHORT
METAANALYSIS
TYPE-1
ANALOG
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
asset.pdf 739.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record